Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01

Fineline Cube Aug 10, 2026
Company Deals

Recursion and Roche‑Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance

Fineline Cube Aug 10, 2026
Company Deals

Kelun-Biotech Signs Commercialization Deal With New Frontier Health for Sacituzumab Tirumotecan in Hong Kong and Macao

Fineline Cube Aug 10, 2026
Company Deals

Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS‑1893 Cardiac Myosin Inhibitor

Fineline Cube Aug 10, 2026
Company Deals Drug

Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML

Fineline Cube Aug 10, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

Huadong Medicine’s Sinclair Secures EU MDR CE Certification for KIO015 Chitosan Skin Booster Kytogen Defend

Fineline Cube Aug 10, 2026
Company Drug

GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D‑Mutant NSCLC in China, First Patient Enrolled

Fineline Cube Aug 10, 2026
Policy / Regulatory

China’s Provincial Governments Implement Second Batch of National Drug Use Monitoring Policy

Fineline Cube Apr 7, 2023

In line with a notification issued by the National Health Commission (NHC) in January, provincial...

Company Drug

Yantai Dongcheng Pharmaceutical Gets Singapore Regulatory Approval for 177Lu-LNC1004 Phase I Study

Fineline Cube Apr 7, 2023

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced receiving the green light...

Company Medical Device

AcoStream Second-Generation Receives NMPA Marketing Approval for Peripheral Vascular Use

Fineline Cube Apr 7, 2023

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving marketing approval from the National...

Company Deals

Shenzhen Kangtai Biological Partners with Biotis for 13-Valent Pneumococcal Vaccine in Indonesia

Fineline Cube Apr 7, 2023

China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has struck a partnership with Indonesian...

Company Deals

Harbour BioMed and AstraZeneca Partner to Advance Pharmaceutical Innovation in Yangtze River Delta

Fineline Cube Apr 7, 2023

Harbour BioMed (HKG: 2142), a biotech with operations in the United States, the Netherlands, and...

Company Deals

Shuwen Biotech’s Subsidiary Signs Promotion Agreement with Sysmex Europe for Breast Cancer Detection Product

Fineline Cube Apr 7, 2023

China-based diagnostic specialist Shuwen Biotech Co., Ltd announced that its wholly-owned German subsidiary, Cerca Biotech...

Company Drug

Vcanbio Receives CDE Approval for VUM02 Clinical Trial in Idiopathic Pulmonary Fibrosis

Fineline Cube Apr 7, 2023

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced receiving clinical trial...

Company Deals

Luye Pharma Group Partners with Duopharma for Exclusive Marketing Rights of TCM in Malaysia

Fineline Cube Apr 7, 2023

China-based Luye Pharma Group (HKG: 2186) has signed an agreement with Malaysia’s Duopharma Marketing Sdn...

Company Deals

Scorpion Therapeutics and Pierre Fabre Collaborate on NSCLC Therapies STX-721 and STX-241

Fineline Cube Apr 7, 2023

US-based Scorpion Therapeutics Inc. has formed a collaboration and license deal with France-based Pierre Fabre,...

Company Deals

Sanofi Partners with Shenzhen’s Pingshan District to Boost Innovative Vaccines in China

Fineline Cube Apr 6, 2023

French pharmaceutical major Sanofi (NASDAQ: SNY) has signed a partnership agreement with the Pingshan district...

Company Drug

Haisco Pharmaceutical Gets CDE Approval for HSK38008 Prostate Cancer Clinical Study

Fineline Cube Apr 6, 2023

Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced receiving approval from the Center for...

Company Drug

Yiling Pharmaceutical’s G201-Na Receives CDE Approval for Phase Ia Study in Prostate Cancer Treatment

Fineline Cube Apr 6, 2023

China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced receiving approval from the Center for...

Company Drug

Mabwell’s 9MW2821 ADC Shows Positive Signals in Solid Tumor Clinical Data

Fineline Cube Apr 6, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced preliminary clinical data for its...

Company Deals R&D

Gates Foundation and NSFC Launch Partnership to Boost Regulatory Science in Vaccine Development

Fineline Cube Apr 6, 2023

The Bill & Melinda Gates Foundation (Gates Foundation) and the National Natural Science Foundation of...

Company Drug

AffaMed Digital Initiates Clinical Study for AMD201 at Beijing Tiantan Hospital

Fineline Cube Apr 6, 2023

AffaMed Digital, a company wholly owned by AffaMed Technologies—a joint venture between AffaMed Therapeutics and...

Policy / Regulatory

Provincial Budgets Highlight Top Earning Hospitals in China for 2023

Fineline Cube Apr 6, 2023

Provincial governments have revealed the budget for provincial hospitals’ expected income during 2023, offering a...

Company Drug

Corxel Pharmaceuticals’ OC-01 Nasal Spray Approved as Urgently Needed Drug in Hainan

Fineline Cube Apr 6, 2023

Shanghai-based Corxel Pharmaceuticals (CORXEL), supported by RTW Investments, has announced that its OC-01 (varenicline) nasal...

Company Deals

Harbour BioMed’s Nona Biosciences Partners with ExeVir Bio to Explore Infectious Disease Sector

Fineline Cube Apr 6, 2023

Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic...

Company

AbbVie’s China General Manager Ou Silang Steps Down, Intercon’s Colzi to Take Interim Role

Fineline Cube Apr 6, 2023

Ou Silang, Vice President and China General Manager of US pharmaceutical major AbbVie (NYSE: ABBV),...

Company Drug

Allist Pharmaceuticals’ Furmonertinib Receives NMPA Approval for Two Clinical Trials

Fineline Cube Apr 6, 2023

Shanghai-based Allist Pharmaceuticals Inc. (SHA: 688578) has announced two clinical trial approvals from the National...

Posts pagination

1 … 580 581 582 … 706

Recent updates

  • China’s 12th National VBP Round Officially Confirmed: 490 Enterprises Selected as Planned Procurement Value Shrinks Over One‑Third to RMB 19.5 Billion
  • Sino Medical Sciences’ Neurovita Wins EU MDR CE Certification for COMETIU, World’s First Intracranial Drug‑Eluting Stent System
  • Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01
  • Huadong Medicine’s Sinclair Secures EU MDR CE Certification for KIO015 Chitosan Skin Booster Kytogen Defend
  • Recursion and Roche‑Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

China’s 12th National VBP Round Officially Confirmed: 490 Enterprises Selected as Planned Procurement Value Shrinks Over One‑Third to RMB 19.5 Billion

Company Medical Device

Sino Medical Sciences’ Neurovita Wins EU MDR CE Certification for COMETIU, World’s First Intracranial Drug‑Eluting Stent System

Company Deals

Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01

Company Drug

Huadong Medicine’s Sinclair Secures EU MDR CE Certification for KIO015 Chitosan Skin Booster Kytogen Defend

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.